Clinical Trial Update: PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on PF-3512676 (CPG 7909) for patients who completed an oncology study using the drug. The document notes that the trial status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• T-cell Lymphoma

Drugs mentioned

• PF-3512676 (CPG 7909) (PF-3512676)

Snippet

Sponsor: Pfizer | Conditions: Melanoma, Breast Neoplasms | Phase 2 | Status: COMPLETED